Riwat Lim Joins MeMed Team as Head of Commercial, Europe
Riwat brings to MeMed extensive commercial experience in the European life sciences industry
HAIFA, Israel, January 18, 2021 – MeMed, a leader in advanced host-immune response technologies, today announces the appointment of Riwat Lim as Head of Commercial, Europe.
Riwat is an experienced executive with a proven track record of commercial success and over 20 years’ experience working in the healthcare sector. He joins MeMed from Spartan Bioscience, where he served as the company’s European Business Lead, overseeing the launch of its precision medicine point-of-care DNA analyser in Europe. Prior to this, Riwat held multiple positions in pharmaceutical and IVD companies including Curetis, Procter & Gamble Pharmaceuticals and Syner-Med. Riwat also served as Head of Market Development Infectious Diseases, Northern Europe at Qiagen, and Head of UK Patient Retention Program at Pfizer.
Dr. Eran Eden, CEO and co-founder of MeMed said: “It is wonderful to welcome Riwat to MeMed to head up our commercial operations in Europe. His experience will be extremely valuable in furthering MeMed’s presence in Europe, and cementing our position as a leading partner-of-choice to help healthcare providers utilize the insights of the host immune response.”
Riwat Lim commented: “I’m extremely excited to be joining the MeMed team to advance the commercialization of its transformative host immune response solutions in Europe. These are technologies that could revolutionize clinical outcomes, helping to rapidly guide clinicians towards improved treatment decisions. It will be fantastic to be a part of bringing these innovations closer to patients in Europe.”
Our mission is to translate the immune system’s complex signals into simple insights that transform the way diseases are diagnosed and treated, profoundly benefiting patients and society. To learn more about MeMed and our solutions, please visit http://www.me-med.com